Feb 23, 2022 / 02:30PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
Great. Well, thanks for joining us here at the Citi Virtual Healthcare Conference. I'm Patrick Donnelly. I'm the tools, diagnostics and CRO analyst here at Citi. Excited to have Jim Foster, CEO of Charles River, here with us today. A very topical time in CRO land to discuss a bunch of different variables. (Operator Instructions)
Questions and Answers:
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior AnalystBut Jim, maybe we can just dive in, maybe not surprisingly, we can start on the funding environment. That's been the biggest question all week, even all year, but certainly has intensified in the last week or so. You guys put up good results. Obviously, you talked really bullishly about the bookings environment.
Maybe you can just talk about the biotech funding elephant in the room. Obviously, again, your commentary, your peers' commentary certainly seems positive outside of one obvious outlier, a kind of your smaller peer. Clearly, the funding
Trustpilot
